CD33 CAR T Cells for AML Targeting and Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloblastic leukemia (AML) face challenges such as high toxicity, limited efficacy, and rapid disappearance of CAR+ T cells, necessitating the development of safer and more effective therapeutic approaches that can specifically target CD33-positive tumor cells without harming normal tissues.
Innovation Solution
The development of chimeric antigen receptors (CARs) containing CD33 antigen binding domains, which are expressed on T cells to enhance cytolysis and persistence, allowing for targeted treatment of AML by binding to CD33 antigens on tumor cells while minimizing impact on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose chemotherapy or radiation is used for remission induction, then treatment efficacy is improved, but toxicity increases
Solution Approach 1:
The treatment approach is segmented into two distinct phases: remission induction using conventional chemotherapy/radiation, followed by consolidation using allogeneic stem cell transplantation. This segmentation allows different treatment modalities to be applied at different stages, optimizing efficacy while managing toxicity through the protective effect of the stem cell transplant.
Solution Approach 2:
Allogeneic stem cell transplantation serves as an intermediary measure that protects patients from the cumulative toxicity of intensive chemotherapy and radiation. The stem cells act as a biological mediator that restores hematopoietic function after high-dose treatment, enabling patients to tolerate higher therapeutic doses while reducing net toxicity.
2Ease of operation
If conventional chemotherapy and radiation are used, then treatment can be administered, but durability of response is limited
Solution Approach 1:
Allogeneic stem cell transplantation is performed as a preliminary consolidation measure after remission induction, preparing the patient's immune system in advance to provide long-term surveillance against leukemia recurrence. This preliminary action establishes a durable immune response before the patient would otherwise experience relapse.
Solution Approach 2:
The treatment protocol ensures continuity of useful action by transitioning from intensive induction chemotherapy to consolidation transplantation, maintaining continuous anti-leukemia pressure. The stem cell graft provides ongoing immune surveillance and cytotoxic activity against residual leukemia cells, extending the duration of therapeutic effect beyond what conventional chemotherapy alone can achieve.
3Manufacturing precision
If CAR+ T cells are used for targeted treatment, then specificity is improved, but persistence and durability are reduced
Solution Approach 1:
Instead of relying on patient's own CAR+ T cells which may have limited persistence, the approach uses allogeneic stem cells that are transduced with CAR genes ex vivo. These engineered stem cells copy and propagate the CAR expression continuously as they differentiate and repopulate the patient's hematopoietic system, ensuring durable CAR+ cell presence rather than the transient persistence of infused CAR+ T cells.
Solution Approach 2:
The allogeneic stem cells serve themselves by continuously self-renewing and differentiating into various blood cell lineages while maintaining CAR expression. This self-service mechanism ensures ongoing production of CAR+ effector cells without requiring repeated infusions, solving the persistence problem of CAR+ T cell therapy.
Data Source
AI summary
Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.